Issue 1/2013

Tumor microenvironment and the role of mesenchymal stromal cells (1 — 10)

L. KUCEROVA, S. SKOLEKOVA

DOI: 10.4149/neo_2013_001

Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy (11 — 18)

W. HUANG, X. DING, B. LI, M. FAN, T. ZHOU, H. SUN, Y. YI, J. ZHANG

DOI: 10.4149/neo_2013_002

Prognostic Analysis of Patients with Operable Gastric Cancer and Tolerability to Adjuvant Radio-Chemo-Therapy (19 — 25)

M. KUCUKONER, E. ARPACI, A. ISIKDOGAN, M. BILICI, D. UNCU, B. CETIN, F. DANE, M. INANC, A. S. EKINCI, A. INAL, K. CAYIR, T. YETISYIGIT, N. OZDEMIR, M. A. KAPLAN, S. AKSOY, N. ALKIS, S. B. TEKIN, C. EROGLU, S. TURHAL, S. BUYUKBERBER

DOI: 10.4149/neo_2013_003

Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical Practice (26 — 32)

O. FIALA, M. PESEK, J. FINEK, J. KREJCI, J. RICAR, Z. BORTLICEK, L. BENESOVA, M. MINARIK

DOI: 10.4149/neo_2013_004

Notch1 overexpression promotes cell growth and tumor angiogenesis in myeloma (33 — 40)

D. GUO, C. LI, Q. TENG, Z. SUN, Y. LI, C. ZHANG

DOI: 10.4149/neo_2013_005

Targeting rictor inhibits mouse vascular tumor cell proliferation and invasion in vitro and tumor growth in vivo (41 — 45)

N. N. ZHENG, X. D. DING, H. P. ZHANG

DOI: 10.4149/neo_2013_006

Rosiglitazone Shows Partial Oncostatic Effect in Rat Mammary Carcinogenesis (46 — 55)

B. BOJKOVA, K. KAJO, M. GARAJOVA, P. KUBATKA, M. PEC, T. KISKOVA, P. ORENDAS, M. KASSAYOVA, M. KORPOVA, M. MIKLOSOVA

DOI: 10.4149/neo_2013_007

Altered Expression of ezrin, E-Cadherin and β-Catenin in Cervical Neoplasia (56 — 61)

E. AUVINEN, O. CARPEN, T. KORPELA, M. RONTY, A. VAHERI, J. TARKKANEN

DOI: 10.4149/neo_2013_008

Sleeve lobectomy as an alternative to pneumonectomy in patients with operable lung cancer (62 — 67)

M. KASPRZYK, W. DYSZKIEWICZ, C. PIWKOWSKI, M. BRUDLO, B. GALECKI, P. GABRYEL, L. GASIOROWSKI

DOI: 10.4149/neo_2013_009

The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab (68 — 73)

K. BENESOVA, K. FORSTEROVA, H. VOTAVOVA, V. CAMPR, J. STRITESKY, Z. VELENSKA, B. PROCHAZKA, R. PYTLIK, M. TRNENY

DOI: 10.4149/neo_2013_010

Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia – a useful tool for early detection of minimal residual disease (74 — 82)

J. POLAK, H. HAJKOVA, C. HASKOVEC, H. CECHOVA, I. MARINOV, D. MIKULENKOVA, J. MARKOVA, M. MARKOVA, A. VITEK, V. VALKOVA

DOI: 10.4149/neo_2013_011

Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma (83 — 91)

V. USAKOVA, K. SEVCIKOVA, J. USAK, Z. BARTOSOVA, M. MIKULOVA, S. SPANIK

DOI: 10.4149/neo_2013_012

RNA-interference-mediated downregulation of Pin1 suppresses tumorigenicity of malignant melanoma A375 cells (92 — 100)

J. JIN, Y. ZHANG, Y. LI, H. ZHANG, H. LI, X. YUAN, X. LI, W. ZHOU, B. XU, C. ZHANG, Z. ZHANG, L. ZHU, X. CHEN

DOI: 10.4149/neo_2013_013

Anisomycin Induces Apoptosis of Glucocorticoid Resistant Acute Lymphoblastic Leukemia CEM-C1 Cells via Activation of Mitogen-Activated Protein Kinases p38 and JNK (101 — 110)

Y. LIU, J. GE, Q. LI, L. GU, X. GUO, Z. G. MA, Y. P. ZHU

DOI: 10.4149/neo_2013_014

Assessing the effect of RET Transmembrane Domain Mutations in receptor self-association capability using the in vivo TOXCAT System (111 — 120)

M. BENEJ, S. FEKECSOVA, M. POTURNAJOVA

DOI: 10.4149/neo_2013_015